THE PROGNOSTIC-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES (MDS) FOLLOWING G-CSF

被引：0
|
作者：
LEBEAU, M
TAYLOR, K
LARSON, R
KOEFFLER, P
NEGRIN, R
SABA, H
GANSER, A
JAKUBOWSKI, A
GABRILOVE, J
MUFTI, GJ
CRUZ, J
LANGLEY, G
VARDIMAN, J
DAVIS, M
GREENBERG, P
机构：
[1] UNIV CHICAGO, CHICAGO, IL 60637 USA
[2] MATER HOSP, BRISBANE, AUSTRALIA
[3] UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA
[4] MOFFITT CANC CTR, TAMPA, FL USA
[5] GOETHE UNIV, FRANKFURT, GERMANY
[6] MEM HOSP, ALBANY, NY USA
[7] UNIV LONDON KINGS COLL HOSP, LONDON SE5 8RX, ENGLAND
[8] WAKE FOREST CANC CTR, WINSTON SALEM, NC USA
[9] VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA
[10] AMGEN INC, THOUSAND OAKS, CA USA
[11] STANFORD UNIV HOSP, STANFORD, CA 94305 USA
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A375 / A375
页数：1
相关论文
共 50 条
  • [1] Efficacy of G-CSF and EPO on the anaemia in patients with myelodysplastic syndromes (MDS).
    HellstromLindberg, E
    Negrin, R
    Stein, R
    Krantz, S
    Vardiman, J
    Ost, A
    Lindberg, G
    Greenberg, P
    BLOOD, 1995, 86 (10) : 1340 - 1340
  • [2] LONG-TERM ADMINISTRATION OF G-CSF IN THE MYELODYSPLASTIC SYNDROMES (MDS)
    YOSHIDA, Y
    UCHINO, H
    MAEKAWA, T
    NOMURA, T
    MIZOGUCHI, H
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 920 - 920
  • [3] Cytogenetic abnormalities at diagnosis are the most important prognostic factor in the myelodysplastic syndromes (MDS)
    Buckstein, R
    Crump, M
    Imrie, K
    Sutton, D
    Pantalony, D
    Sher, G
    Stewart, AK
    Keating, A
    BLOOD, 1996, 88 (10) : 2317 - 2317
  • [4] PROGNOSTIC-SIGNIFICANCE OF CHROMOSOMAL-ABNORMALITIES IN ACUTE LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES
    YUNIS, JJ
    BRUNNING, RD
    CLINICS IN HAEMATOLOGY, 1986, 15 (03): : 597 - 620
  • [5] MYELODYSPLASTIC SYNDROMES - A SCORING SYSTEM WITH PROGNOSTIC-SIGNIFICANCE
    MUFTI, GJ
    STEVENS, JR
    OSCIER, DG
    HAMBLIN, TJ
    MACHIN, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 59 (03) : 425 - 433
  • [6] Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of high risk myelodysplastic syndromes (MDS).
    Ferrara, F
    Mirto, S
    Montillo, M
    Mele, G
    Tedeschi, A
    Ciolli, S
    Annunziata, M
    Copia, C
    Magrin, S
    Leoni, F
    BLOOD, 1997, 90 (10) : 371 - 371
  • [7] Treatment of myelodysplastic syndromes with erythropoietin and G-CSF
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2007, 31 : S17 - S17
  • [8] Erythropoietic effectiveness and apoptosis in patients with myelodysplastic syndromes (MDS) treated with G-CSF and EPO.
    Kanter, L
    HellstromLindberg, E
    Kock, Y
    Rodensjo, M
    Ost, A
    BLOOD, 1995, 86 (10) : 1339 - 1339
  • [9] PROGNOSTIC-SIGNIFICANCE OF A SCORING STAGING SYSTEM FOR MYELODYSPLASTIC SYNDROMES
    PASQUALETTI, P
    NATALI, L
    MEDICINA-RIVISTA DELLA ENCICLOPEDIA MEDICA ITALIANA, 1987, 7 (03): : 321 - 323
  • [10] Assessment of apoptosis in relation to single cytogenetic abnormalities in myelodysplastic syndromes (MDS).
    Mundle, S
    Hsu, WT
    Dutt, D
    Dar, S
    Saberwal, G
    Townsend, W
    Broderick, E
    Kaspar, C
    Alvi, S
    Shetty, V
    Allampallam, K
    Reddy, P
    Venugopal, P
    Gezer, S
    Lisak, L
    Raza, A
    BLOOD, 2001, 98 (11) : 191B - 191B
12345